Christina Linder-Stragliotto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christina Linder-Stragliotto has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Felix Haglund de Flon
Department of Oncology‐Pathology Karolinska Institutet Stockholm Sweden
25 shared publications - Panagiotis Tsagkozis
Department of Molecular Medicine and Surgery, Karolinska Institutet, 171 76 Stockholm, Sweden
25 shared publications - Andri Papakonstantinou
Department of Oncology‐Pathology Karolinska Institutet Stockholm Sweden
24 shared publications - Anna Gellerbring
Science for Life Laboratory, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
23 shared publications - Annick Renevey
Bernhard Nocht Institute for Tropical Medicine (BNITM), Hamburg, Germany
23 shared publications - Cecilia Haglund
Department of Oncology-Pathology, Karolinska Institutet, Solna, Sweden
23 shared publications
Latest Publications
- Open Access
- 13 April 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (10) , 4873-4884
Drug sensitivity testing of patient-derived bone sarcomas identifies selective kinase inhibitors for patients with refractory disease
Objective: This study aimed to investigate the feasibility and predictive value in performing ex vivo drug sensitivity testing on bone sarcomas from patients with refractory disease and identify agents with potential therapeutic benefit. Methods: A cohort of 7 osteosarcomas (OS) and 4 Ewing sarcoma (ES) patient-derived cells (PDCs) were screened against a library of oncological drugs, gene panel sequencing and mRNA expression arrays. Drug responses were correlated to the molecular characteristics of specific sarcoma subtypes and patient response to therapy. Results: OS PDCs showed heterogeneous drug sensitivity, with observed responses for mTOR, PKC, MAPK and CDK inhibitors that correlated with the histological subtype and genotype of the primary tumor. Two of 4 ES PDCs displayed morphological dichotomy as separate Ews-Fli1 positive spheroid and adherent populations. These ES PDCs showed comparable responses to most of the oncological drugs but differential sensitivity to rapalogs and SMAC-mimetics. In both, OS and ES, the drug sensitivity of PDCs correlated to the patient response to chemotherapy. Conclusion: Drug sensitivity testing of PDCs from bone sarcomas is a valuable tool for a rapid identification of potential treatments, in otherwise genetically complex group of tumors where genome-based assays are difficult to implement. Clones with different phenotypes can outgrow in PDC cultures and can represent clonal evolution that give raise to tumor recurrence.
- 13 April 2026
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (10) , 4873-4884
Open AccessDrug sensitivity testing of patient-derived bone sarcomas identifies selective kinase inhibitors for patients with refractory disease
Objective: This study aimed to investigate the feasibility and predictive value in performing ex vivo drug sensitivity testing on bone sarcomas from patients with refractory disease and identify agents with potential therapeutic benefit. Methods: A cohort of 7 osteosarcomas (OS) and 4 Ewing sarcoma (ES) patient-derived cells (PDCs) were screened against a library of oncological drugs, gene panel sequencing and mRNA expression arrays. Drug responses were correlated to the molecular characteristics of specific sarcoma subtypes and patient response to therapy. Results: OS PDCs showed heterogeneous drug sensitivity, with observed responses for mTOR, PKC, MAPK and CDK inhibitors that correlated with the histological subtype and genotype of the primary tumor. Two of 4 ES PDCs displayed morphological dichotomy as separate Ews-Fli1 positive spheroid and adherent populations. These ES PDCs showed comparable responses to most of the oncological drugs but differential sensitivity to rapalogs and SMAC-mimetics. In both, OS and ES, the drug sensitivity of PDCs correlated to the patient response to chemotherapy. Conclusion: Drug sensitivity testing of PDCs from bone sarcomas is a valuable tool for a rapid identification of potential treatments, in otherwise genetically complex group of tumors where genome-based assays are difficult to implement. Clones with different phenotypes can outgrow in PDC cultures and can represent clonal evolution that give raise to tumor recurrence.
- Open Access
- 3 February 2026
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 65, 32-35
Eribulin-induced resolution of high-risk basal cell carcinoma: implications for microtubule-targeting agents in BCC management: a case report
- 3 February 2026
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 65, 32-35
Open AccessEribulin-induced resolution of high-risk basal cell carcinoma: implications for microtubule-targeting agents in BCC management: a case report
- Open Access
- 21 November 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (11) , e70406
Oncological Outcome for 83 Consecutive Patients With Malignant Peripheral Nerve Sheath Tumors Treated at a Tertiary Referral Centre
Background: Malignant peripheral nerve sheath tumors (MPNSTs) are rare soft tissue sarcomas with a high risk of recurrence and a poor prognosis, and there is a lack of knowledge regarding long‐term follow‐up and response to oncological treatment. Aims: The aim of this study was to investigate what treatment the patients received and to examine the outcome for patients with MPNST. Methods and Results: This is a retrospective study of patients treated for MPNST at Karolinska University Hospital between 2003 and 2022. Data regarding surgical and oncological treatment and follow‐up were collected. Eighty‐three patients were identified and included in the study. Tumor grade is available for 72 patients, of which 64 had high‐grade tumors. Seventy‐nine patients were primarily operated on. Twelve patients presented with distant metastases at diagnosis. Another 37 patients developed local recurrence or distant metastases during follow‐up; the median time from surgery to recurrence was 10.5 months (1–95 months, n = 36). The overall mortality rate during the study period was 44% ( n = 82). Twenty‐seven patients received palliative systemic treatment. The most used therapy for first‐line palliative systemic treatment was doxorubicin and ifosfamide. The disease control rate for first‐line treatment was 33% ( n = 21). The mean overall survival for the cohort was 132 months (95% CI 107–157 months). Conclusion: Forty‐five percent of the patients in this material were diagnosed with recurrent disease and most patients treated with palliative systemic therapy experienced brief disease control following treatment. Among patients with MPNST treated with first‐line palliative oncological treatment, doxorubicin and ifosfamide have the highest disease control rates. The study also identified a few patients with long‐term treatment responses, with four patients alive more than 2 years after starting palliative oncological treatment.
- 21 November 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (11) , e70406
Open AccessOncological Outcome for 83 Consecutive Patients With Malignant Peripheral Nerve Sheath Tumors Treated at a Tertiary Referral Centre
Background: Malignant peripheral nerve sheath tumors (MPNSTs) are rare soft tissue sarcomas with a high risk of recurrence and a poor prognosis, and there is a lack of knowledge regarding long‐term follow‐up and response to oncological treatment. Aims: The aim of this study was to investigate what treatment the patients received and to examine the outcome for patients with MPNST. Methods and Results: This is a retrospective study of patients treated for MPNST at Karolinska University Hospital between 2003 and 2022. Data regarding surgical and oncological treatment and follow‐up were collected. Eighty‐three patients were identified and included in the study. Tumor grade is available for 72 patients, of which 64 had high‐grade tumors. Seventy‐nine patients were primarily operated on. Twelve patients presented with distant metastases at diagnosis. Another 37 patients developed local recurrence or distant metastases during follow‐up; the median time from surgery to recurrence was 10.5 months (1–95 months, n = 36). The overall mortality rate during the study period was 44% ( n = 82). Twenty‐seven patients received palliative systemic treatment. The most used therapy for first‐line palliative systemic treatment was doxorubicin and ifosfamide. The disease control rate for first‐line treatment was 33% ( n = 21). The mean overall survival for the cohort was 132 months (95% CI 107–157 months). Conclusion: Forty‐five percent of the patients in this material were diagnosed with recurrent disease and most patients treated with palliative systemic therapy experienced brief disease control following treatment. Among patients with MPNST treated with first‐line palliative oncological treatment, doxorubicin and ifosfamide have the highest disease control rates. The study also identified a few patients with long‐term treatment responses, with four patients alive more than 2 years after starting palliative oncological treatment.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500377
Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium
PURPOSE: Updated analysis of phase I/II trials in recurrent/refractory (R/R) Ewing sarcoma (EwS) over the past 11 years. METHODS: A systematic review was performed to identify phase I/II trials for R/R EwS in three databases (WHO, US National Library of Medicine, and European Clinical Trials Database) and/or published in PubMed/ASCO/European Society for Medical Oncology websites from 2014 to 2024. The search criteria included EwS OR bone sarcoma OR sarcoma AND Phase-I OR Phase-II. Eligibility and data extraction were performed independently by three reviewers, with priority given to trials with EwS specified data. Trials were categorized by therapeutic intervention, including targeted therapies, immunotherapy, chemotherapy, and combined therapies. RESULTS: One hundred eight trials met inclusion criteria, predominantly academic (70%) and multicenter (81.5%), with significant US and European collaboration. Trial designs were mainly single-arm, with an increase in multiarm trials in the recent years and increased focus on the pediatric population. Trial modalities emphasized targeted therapies with tyrosine kinase, poly-ADP ribose polymerase, EWSR1::FLI1, and cell cycle inhibitors. Immunotherapy with monoclonal antibodies and CAR-T cells as primary agents is also under investigation. The COVID-19 pandemic coincided with a marked reduction in trial initiation in 2020. Among evaluable data, disease control rates averaged 44% and response rates 8%. CONCLUSION: This review highlights evolving therapeutic directions in R/R EwS, with increased emphasis on targeted therapies and immunotherapies. Despite pandemic-related delays, trials have progressed in exploring novel targets, including EWSR1::FLI1 oncogenic fusion and DNA repair pathways. These findings underscore ongoing global efforts to address critical unmet needs in EwS treatment, offering a foundation for future trial designs, especially international, randomized phase‐II trials across all age ranges.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 9 (9) , e2500377
Recurrent and Refractory Ewing Sarcoma Phase I/II Trials: Current Perspective From the Euro-Ewing Consortium
PURPOSE: Updated analysis of phase I/II trials in recurrent/refractory (R/R) Ewing sarcoma (EwS) over the past 11 years. METHODS: A systematic review was performed to identify phase I/II trials for R/R EwS in three databases (WHO, US National Library of Medicine, and European Clinical Trials Database) and/or published in PubMed/ASCO/European Society for Medical Oncology websites from 2014 to 2024. The search criteria included EwS OR bone sarcoma OR sarcoma AND Phase-I OR Phase-II. Eligibility and data extraction were performed independently by three reviewers, with priority given to trials with EwS specified data. Trials were categorized by therapeutic intervention, including targeted therapies, immunotherapy, chemotherapy, and combined therapies. RESULTS: One hundred eight trials met inclusion criteria, predominantly academic (70%) and multicenter (81.5%), with significant US and European collaboration. Trial designs were mainly single-arm, with an increase in multiarm trials in the recent years and increased focus on the pediatric population. Trial modalities emphasized targeted therapies with tyrosine kinase, poly-ADP ribose polymerase, EWSR1::FLI1, and cell cycle inhibitors. Immunotherapy with monoclonal antibodies and CAR-T cells as primary agents is also under investigation. The COVID-19 pandemic coincided with a marked reduction in trial initiation in 2020. Among evaluable data, disease control rates averaged 44% and response rates 8%. CONCLUSION: This review highlights evolving therapeutic directions in R/R EwS, with increased emphasis on targeted therapies and immunotherapies. Despite pandemic-related delays, trials have progressed in exploring novel targets, including EWSR1::FLI1 oncogenic fusion and DNA repair pathways. These findings underscore ongoing global efforts to address critical unmet needs in EwS treatment, offering a foundation for future trial designs, especially international, randomized phase‐II trials across all age ranges.
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
Supplementary Data 2 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
Supplementary Data 2 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 7 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
Supplementary Data 7 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 7 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
Supplementary Data 7 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
Supplementary Data 1 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
Supplementary Data 1 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 6 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
Supplementary Data 6 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 6 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
Supplementary Data 6 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 3 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
Supplementary Data 3 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 3 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
Supplementary Data 3 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
- Open Access
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 9 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
Supplementary Data 9 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
- 14 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 9 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma
Supplementary Data 9 from Comprehensive Genomic Profiling Alters Clinical Diagnoses in a Significant Fraction of Tumors Suspicious of Sarcoma